Sign in to view content

Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases

Matthew Starr, MD

Video
Published 2022

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO
Suber S. Huang, MD, MBA, FASRS
Annual Meeting Talks
2021
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022

Category: Diabetic Retinopathy

See more